VistaGen Therapeutics (VTGN) Competitors $3.25 -0.14 (-4.13%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$3.20 -0.05 (-1.66%) As of 04:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTGN vs. SLDB, ATXS, NBTX, FULC, CGEM, KMDA, INBX, AURA, ADCT, and PRTCShould you be buying VistaGen Therapeutics stock or one of its competitors? The main competitors of VistaGen Therapeutics include Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Nanobiotix (NBTX), Fulcrum Therapeutics (FULC), Cullinan Therapeutics (CGEM), Kamada (KMDA), Inhibrx Biosciences (INBX), Aura Biosciences (AURA), ADC Therapeutics (ADCT), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry. VistaGen Therapeutics vs. Its Competitors Solid Biosciences Astria Therapeutics Nanobiotix Fulcrum Therapeutics Cullinan Therapeutics Kamada Inhibrx Biosciences Aura Biosciences ADC Therapeutics PureTech Health Solid Biosciences (NASDAQ:SLDB) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends. Is SLDB or VTGN more profitable? Solid Biosciences has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -6,777.08%. Solid Biosciences' return on equity of -69.70% beat VistaGen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Solid BiosciencesN/A -69.70% -56.74% VistaGen Therapeutics -6,777.08%-74.06%-64.10% Does the media refer more to SLDB or VTGN? In the previous week, Solid Biosciences had 1 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 4 mentions for Solid Biosciences and 3 mentions for VistaGen Therapeutics. Solid Biosciences' average media sentiment score of 1.20 beat VistaGen Therapeutics' score of 0.30 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VistaGen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in SLDB or VTGN? 81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are held by institutional investors. 13.6% of Solid Biosciences shares are held by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, SLDB or VTGN? VistaGen Therapeutics has lower revenue, but higher earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSolid Biosciences$8.09M52.84-$124.70M-$2.80-1.96VistaGen Therapeutics$490K203.49-$51.42M-$1.78-1.83 Which has more risk and volatility, SLDB or VTGN? Solid Biosciences has a beta of 2.54, indicating that its stock price is 154% more volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Do analysts prefer SLDB or VTGN? Solid Biosciences currently has a consensus price target of $15.00, indicating a potential upside of 173.22%. Given Solid Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Solid Biosciences is more favorable than VistaGen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solid Biosciences 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09VistaGen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummarySolid Biosciences beats VistaGen Therapeutics on 13 of the 17 factors compared between the two stocks. Get VistaGen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTGN vs. The Competition Export to ExcelMetricVistaGen TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$104.01M$3.15B$5.80B$10.16BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-1.8321.2475.1126.39Price / Sales203.49431.67511.76177.24Price / CashN/A44.4425.8129.91Price / Book1.339.6413.456.28Net Income-$51.42M-$53.20M$3.29B$270.38M7 Day Performance-9.97%0.07%0.08%1.89%1 Month Performance-1.81%4.27%4.59%6.01%1 Year Performance3.17%9.62%75.30%25.26% VistaGen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTGNVistaGen Therapeutics0.9882 of 5 stars$3.25-4.1%N/A-1.2%$104.01M$490K-1.8340News CoverageShort Interest ↑SLDBSolid Biosciences3.1482 of 5 stars$5.13-6.7%$15.00+192.4%-30.8%$428.28M$8.09M-1.83100Positive NewsAnalyst DowngradeATXSAstria Therapeutics2.8514 of 5 stars$7.43-1.2%$29.00+290.3%-33.8%$424.39MN/A-3.7030Positive NewsNBTXNanobiotix0.6401 of 5 stars$8.71+0.1%$8.00-8.2%+88.3%$417.11M$39.18M0.00100Upcoming EarningsShort Interest ↑FULCFulcrum Therapeutics2.6237 of 5 stars$7.27-5.1%$7.57+4.1%+122.3%$414.34M$80M-5.96100News CoveragePositive NewsShort Interest ↓CGEMCullinan Therapeutics2.1908 of 5 stars$6.84-2.1%$26.80+291.8%-64.6%$412.93MN/A-2.1230KMDAKamada4.5475 of 5 stars$7.22+1.1%$13.00+80.1%+25.1%$410.59M$169.52M21.24360Positive NewsShort Interest ↓INBXInhibrx Biosciences1.2954 of 5 stars$29.10+3.3%N/A+65.6%$408.20M$200K-2.75166News CoveragePositive NewsAURAAura Biosciences2.1941 of 5 stars$6.47-0.2%$22.00+240.0%-40.7%$402.54MN/A-3.3050Positive NewsADCTADC Therapeutics3.018 of 5 stars$3.51-0.8%$7.75+120.6%+3.4%$398.25M$70.84M-2.24310Positive NewsPRTCPureTech Health0.5517 of 5 stars$16.42+1.2%$45.00+174.1%-21.6%$391.70M$4.83M0.00100Short Interest ↑ Related Companies and Tools Related Companies SLDB Alternatives ATXS Alternatives NBTX Alternatives FULC Alternatives CGEM Alternatives KMDA Alternatives INBX Alternatives AURA Alternatives ADCT Alternatives PRTC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTGN) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VistaGen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VistaGen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VTGN Stock Alerts